Skip to main content
. 2021 Jul 13;19:48. doi: 10.1186/s12959-021-00301-x

Table 4.

Bi-variable and multi-variable logistic regression analysis of factors associated with PIVC phlebitis among admitted patients at University of Gondar hospital, Northwest Ethiopia, April 1, 2020 to August 31, 2020

Variables Phlebitis COR (CI) P-value AOR (CI) P-value
Yes No
Age (years)
 18–40 42 127 1 1
 40–60 43 82 1.59 (0.91–2.77) 0.104 1.19 (0.55–2.58) 0.650
 > 60 31 59 1.02 (0.57–1.77) 0.995 0.89 (0.45–1.75) 0.730
Gender
 Male 128 71 1 1
 Female 140 454 0.58 (0.37–0.90) 0.016 0.29 (0.13–0.63) 0.002
Residence
 Urban 119 60 1 1
 Rural 149 56 0.75 (0.48–1.15) 0.187 0.65 (0.33–1.28) 0.209
Religion
 Christian 246 97 1 1
 Muslim 23 18 2.07 (1.06–4.02) 0.033 1.86 (0.71–4.91) 0.210
Educational level
 Unable to read and write 126 41 1 1
 Able to read and write 28 23 1.09 (0.54–2.20) 0.817 1.53 (0.47–5.02) 0.483
 Elementary school 44 23 0.47 (0.21–1.08) 0.077 0.77 (0.23–2.62) 0.680
 Secondary school 37 12 0.74 (0.34–1.65) 0.467 1.04 (0.33–3.31) 0.942
 College and above 36 14 1.19 (0.49–2.94) 0.692 1.86 (0.59–5.75) 0.284
Admission diagnosis
 Lung disease 69 28 1
 Heart disease 42 26 0.90 (0.47–1.72) 0.749 1.3 (0.6–2.81) 0.511
 CNS disease 47 18 0.59 (0.3–1.17) 0.130 0.75 (0.33–1.70) 0.488
 Liver disease 17 4 0.95 (0.46–1.97) 0.897 1.32 (0.56–3.09) 0.522
 Renal disease 8 8 1.55 (0.47–5.10) 0.469 1.74 (0.48–6.34) 0.404
 Hematological diseases 12 6 1.22 (0.31–4.82) 0.78 1.19 (0.26–5.46) 0.826
 Fracture 10 3 0.37 (0.12–1.09) 0.07 0.45 (0.12–1.64) 0.225
 Others 63 23 0.57 (0.25–2.17) 0.572 1.3 (0.37–4.59) 0.688
Co-morbidities
 Diabetes
  Yes 26 12 1.07 (0.52–2.21) 0.85
  No 242 104 1
 Hypertension
  Yes 57 32 0.71 (0.43–1.17) 0.179 1.08 (0.57–2.05) 0.804
  No 211 84 1 1
 HIV/AIDS
  Yes 12 12 1 1
  No 115 44 0.43 (0.18–1.00) 0.050 0.56 (0.20–1.58) 0.275
  Unknown 141 60 1.11 (0.70–1.76) 0.651 1.22 (0.71–2.11) 0.488
 CKD
  Yes 20 10 1.17 (0.53–2.58) 0.69
  No 250 104 1
 Malignancy
  Yes 22 8 1.07 (0.50–2.54) 0.64
  No 248 106 1
 Concomitant bacterial infections
 Yes 168 75 1.09 (0.69–1.72) 0.71
  No 100 41 1
Duration of hospital stay
 < 3 days 19 7 1 1
 3–7 days 89 31 1.47 (0.55–3.93) 0.447 1.75 (0.56–5.48) 0.338
 7–14 days 110 51 1.55 (0.83–2.89) 0.167 1.73 (0.85–3.53) 0.131
 > 14 days 50 27 1.17 (0.66–2.07) 0.603 1.21 (0.63–2.32) 0.563
Place of procedure
 Emergency unit 146 57 1
 Wards 122 59 0.60 (0.07–5.70) 0.65
Catheter dwell time
 < 3 days 119 52 1 1
 3–4 days 66 17 1.3 (0.8–2.10) 0.294 1.21 (0.68–2.15) 0.511
 > 4 days 83 47 2.2 (1.16–4.18) 0.016 2.26 (1.09–4.70) 0.029
Cannula insertion site
 Dorsum of hand 95 53 0.85 (0.61–1.24) 0.422
 Forearm 144 57 0.91 (0.55–2.20) 0.652
 Antecubital fossa 29 6 1
Cannula size (gauge)
 18 4120 1
 20 218 93 1.00 (0.63–1.98) 1.000
 22 6 2 0.78 (0.16–3.94) 0.761
 24 3 1 0.68 (0.13–3.69) 0.660
Intravenous drugs use
 Yes 202 80 0.73 (0.45–1.18) 0.193 0.88 (0.49–1.59) 0.682
 No 66 36 1 1
Intravenous infusates use
 Yes 189 62 0.48 (0.31–0.75) 0.001 0.47 (0.28–0.79) 0.005
 No 79 54 1 1
Blood products use
 Yes 37 15 0.93 (0.49–1.77) 0.82
 No 231 101 1

NB AIDS, acquired immune deficiency syndrome, AOR adjusted odds ratio, COR crude odds ratio, CI confidence interval, CKD chronic kidney disease, HIV human immune deficiency virus, PIVC peripheral intravenous catheter